Key facts
- Neuromod’s last known valuation is $49.3M (Mar 2025).
- It has raised $71.7M; the latest was Later Stage VC ($10.7M) in Mar 2025.
- Notable investors include Enterprise Ireland, SVB Financial Group (Dallas), NDRC, Panakes Partners, British Standards Institution — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Neuromod
- ·The full record, as it builds
Funding rounds
No funding rounds for Neuromod are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Neuromod
Developer of a medical technology designed to stimulate progress through the design, clinical validation, and commercialization of neuromodulation technologies. The company utilizes bi-modal neuromodulation to deliver effective targeted neurostimulation, enabling patients to take control of their treatment by adopting targeted therapies that integrate seamlessly into a modern lifestyle.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2010
- Employees
- 65
- Website
- neuromod.com/
- Ownership
- Privately Held (backing)
Neuromod doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Neuromod shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Neuromod in its N-PORT filings yet. We sweep new filings monthly.